Dynamic Technology Lab Private Ltd Buys New Holdings in United Therapeutics Corporation (UTHR)

Dynamic Technology Lab Private Ltd bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,199 shares of the biotechnology company’s stock, valued at approximately $285,000.

Other hedge funds also recently made changes to their positions in the company. Eagle Global Advisors LLC bought a new stake in shares of United Therapeutics Corporation during the 2nd quarter worth about $206,000. TLP Group LLC bought a new stake in shares of United Therapeutics Corporation during the 2nd quarter worth about $246,000. HPM Partners LLC boosted its holdings in shares of United Therapeutics Corporation by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after buying an additional 15 shares during the period. Fort L.P. boosted its holdings in shares of United Therapeutics Corporation by 5.2% during the 2nd quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock worth $261,000 after buying an additional 99 shares during the period. Finally, Prospera Financial Services Inc bought a new stake in shares of United Therapeutics Corporation during the 2nd quarter worth about $277,000.

UTHR has been the subject of several research analyst reports. UBS AG reaffirmed a “sell” rating and set a $106.00 target price on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Zacks Investment Research downgraded shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. ValuEngine raised shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a report on Friday, July 14th. Finally, BidaskClub downgraded shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Five analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. United Therapeutics Corporation currently has an average rating of “Hold” and an average price target of $132.82.

COPYRIGHT VIOLATION NOTICE: This article was published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/10/30/dynamic-technology-lab-private-ltd-buys-new-holdings-in-united-therapeutics-corporation-uthr.html.

In other news, CEO Martine A. Rothblatt sold 1,263 shares of the firm’s stock in a transaction that occurred on Thursday, October 26th. The shares were sold at an average price of $120.38, for a total value of $152,039.94. Following the completion of the transaction, the chief executive officer now directly owns 1,403 shares in the company, valued at $168,893.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total transaction of $77,998.40. Following the completion of the transaction, the director now owns 3,295 shares of the company’s stock, valued at $443,111.60. The disclosure for this sale can be found here. Insiders sold 18,368 shares of company stock valued at $2,295,419 over the last 90 days. 7.80% of the stock is owned by company insiders.

Shares of United Therapeutics Corporation (UTHR) opened at 120.05 on Monday. The company has a market cap of $5.22 billion, a P/E ratio of 13.92 and a beta of 1.50. The stock’s 50 day moving average is $120.33 and its 200-day moving average is $125.64. United Therapeutics Corporation has a one year low of $112.01 and a one year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, beating analysts’ consensus estimates of $4.01 by $2.26. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The company had revenue of $445.50 million during the quarter, compared to analyst estimates of $426.43 million. During the same period last year, the business earned $4.23 earnings per share. United Therapeutics Corporation’s revenue was up 9.1% compared to the same quarter last year. Equities research analysts forecast that United Therapeutics Corporation will post $10.60 earnings per share for the current year.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

What are top analysts saying about United Therapeutics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for United Therapeutics Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit